Teacher Retirement System of Texas Sells 938 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Teacher Retirement System of Texas reduced its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 7.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,922 shares of the company’s stock after selling 938 shares during the period. Teacher Retirement System of Texas’ holdings in Vera Therapeutics were worth $286,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Huntington National Bank bought a new position in shares of Vera Therapeutics in the fourth quarter worth approximately $26,000. AlphaQuest LLC bought a new position in shares of Vera Therapeutics in the fourth quarter worth approximately $34,000. GF Fund Management CO. LTD. bought a new position in shares of Vera Therapeutics in the fourth quarter worth approximately $56,000. Summit Investment Advisors Inc. grew its holdings in shares of Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after purchasing an additional 639 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Vera Therapeutics by 1,779.1% in the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company’s stock worth $199,000 after purchasing an additional 7,846 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wedbush cut their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Cantor Fitzgerald cut their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Scotiabank reiterated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $65.00.

Insider Activity

In other news, Director Patrick G. Enright purchased 209,393 shares of the business’s stock in a transaction on Monday, June 23rd. The stock was acquired at an average cost of $20.87 per share, for a total transaction of $4,370,031.91. Following the purchase, the director directly owned 3,569,522 shares in the company, valued at $74,495,924.14. This trade represents a 6.23% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 16.30% of the stock is currently owned by corporate insiders.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $23.05 on Friday. The company has a current ratio of 27.68, a quick ratio of 27.68 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.47 billion, a P/E ratio of -7.68 and a beta of 1.19. The business has a fifty day simple moving average of $22.78 and a two-hundred day simple moving average of $26.79. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the firm earned ($0.56) earnings per share. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.